Immunic says cash and cash equivalents expected to fund operations into q1 of 2021

Immunic, inc. reports year end 2019 financial results and highlights recent achievements.immunic inc - top-line data from phase 2 emphasis trial in relapsing-remitting multiple sclerosis expected in q3 2020.immunic inc - cash and cash equivalents, as of december 31, 2019, of $29.4 million, is expected to fund company's operations into q1 of 2021.
IMUX Ratings Summary
IMUX Quant Ranking